Search: onr:"swepub:oai:lup.lub.lu.se:c24ba2fe-696d-4046-8a41-f2298da25d1c" > Off-label use of ri...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05892naa a2200721 4500 | |
001 | oai:lup.lub.lu.se:c24ba2fe-696d-4046-8a41-f2298da25d1c | |
003 | SwePub | |
008 | 161006s2016 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:227651920 | |
024 | 7 | a https://lup.lub.lu.se/record/c24ba2fe-696d-4046-8a41-f2298da25d1c2 URI |
024 | 7 | a https://doi.org/10.1136/lupus-2016-0001632 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:2276519202 URI |
040 | a (SwePub)lud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a for2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Ryden-Aulin, Monicau Karolinska Institutet4 aut |
245 | 1 0 | a Off-label use of rituximab for systemic lupus erythematosus in Europe |
264 | c 2016-09-06 | |
264 | 1 | b BMJ,c 2016 |
520 | a Objectives: Rituximab (RTX) is a biological treatment used off-label in patients with systemic lupus erythematosus (SLE). This survey aimed to investigate the off-label use of RTX in Europe and compare the characteristics of patients receiving RTX with those receiving conventional therapy. Methods: Data on patients with SLE receiving RTX were taken from the International Registry for Biologics in SLE retrospective registry and complemented with data on patients with SLE treated with conventional therapy. For nationwide estimates of RTX use in patients with SLE, investigators were asked to provide data through case report forms (CRFs). Countries for which no data were submitted through CRFs, published literature and/or personal communication were used, and for European countries where no data were available, estimates were made on the assumption of similarities with neighbouring countries. Results: The estimated off-label use of RTX in Europe was 0.5%-1.5% of all patients with SLE. In comparison with patients with SLE on conventional therapy, patients treated with RTX had longer disease duration, higher disease activity and were more often treated with immunosuppressives. The most frequent organ manifestations for which either RTX or conventional therapy was initiated were lupus nephritis followed by musculoskeletal and haematological. The reason for treatment was, besides disease control, corticosteroid-sparing for patients treated with conventional therapy. Conclusions: RTX use for SLE in Europe is restrictive and appears to be used as a last resort in patients for whom other reasonable options have been exhausted. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Reumatologi och inflammation0 (SwePub)302102 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Rheumatology and Autoimmunity0 (SwePub)302102 hsv//eng |
700 | 1 | a Boumpas, Dimitriosu National and Kapodistrian University of Athens4 aut |
700 | 1 | a Bultink, Ireneu Amsterdam Rheumatology and Immunology Center4 aut |
700 | 1 | a Rubio, Jose Luis Callejasu Hospital Clínico Universitario San Cecilio4 aut |
700 | 1 | a Caminal-Montero, Luisu Asturias General Hospital4 aut |
700 | 1 | a Castro, Antoniu Rovira i Virgili University (URV)4 aut |
700 | 1 | a Ruiz, Agustín Colodrou Pasaje Nueva Victoria4 aut |
700 | 1 | a Doria, Andreau University of Padova4 aut |
700 | 1 | a Dorner, Thomasu Charité - University Medicine Berlin4 aut |
700 | 1 | a Gonzalez-Echavarri, Cristinau University of the Basque Country4 aut |
700 | 1 | a Gremese, Elisau Catholic University of the Sacred Heart, Rome4 aut |
700 | 1 | a Houssiau, Frederic A.u Saint-Luc University Hospital4 aut |
700 | 1 | a Huizinga, Tomu Leiden University Medical Centre4 aut |
700 | 1 | a Inanc, Muratu Istanbul University4 aut |
700 | 1 | a Isenberg, Davidu Royal Free Hospital4 aut |
700 | 1 | a Iuliano, Annamariau Azienda Ospedaliera San Camillo Forlanini4 aut |
700 | 1 | a Jacobsen, Sorenu University of Copenhagen4 aut |
700 | 1 | a Jimenez-Alonso, Juanu Hospital Clínico Universitario San Cecilio4 aut |
700 | 1 | a Kovacs, Laszlou University of Szeged4 aut |
700 | 1 | a Mariette, Xavieru Center For Immunology Of Viral Infections And Autoimmune Diseases4 aut |
700 | 1 | a Mosca, Martau University of Pisa4 aut |
700 | 1 | a Nived, Olau Lund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital4 aut0 (Swepub:lu)reum-oni |
700 | 1 | a Oristrell, Joaquimu Autonomous University of Barcelona4 aut |
700 | 1 | a Ramos-Casals, Manuelu Institutd' Investigacions Biomèdiques August Pi iSunyer (IDIBAPS)4 aut |
700 | 1 | a Rascon, Javier4 aut |
700 | 1 | a Ruiz-Irastorza, Guillermou University of the Basque Country4 aut |
700 | 1 | a Sáez-Comet, Luisu Miguel Servet University Hospital4 aut |
700 | 1 | a Cervello, Gonzalo Salvadoru University and Polytechnic Hospital la Fe4 aut |
700 | 1 | a Sebastiani, Gian Domenicou Azienda Ospedaliera San Camillo Forlanini4 aut |
700 | 1 | a Squatrito, Danilou University of Florence4 aut |
700 | 1 | a Szucs, Gabriellau University of Debrecen4 aut |
700 | 1 | a Voskuyl, Alexandreu Amsterdam UMC - Vrije Universiteit Amsterdam4 aut |
700 | 1 | a Van Vollenhoven, Ronaldu Karolinska Institutet4 aut |
710 | 2 | a Karolinska Institutetb National and Kapodistrian University of Athens4 org |
773 | 0 | t Lupus Science and Medicined : BMJg 3:1q 3:1x 2053-8790 |
856 | 4 | u http://dx.doi.org/10.1136/lupus-2016-000163x freey FULLTEXT |
856 | 4 | u https://lupus.bmj.com/content/lupusscimed/3/1/e000163.full.pdf |
856 | 4 8 | u https://lup.lub.lu.se/record/c24ba2fe-696d-4046-8a41-f2298da25d1c |
856 | 4 8 | u https://doi.org/10.1136/lupus-2016-000163 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:227651920 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.